Recent clinical and experimental studies indicate that NRF2 activity correlates with distinct aspects of the tumor–node–metastasis (TNM) classification for malignant tumors, particularly with increased tumor invasion (T) and metastatic spread (M)—two dimensions strongly associated with poor patient prognosis. Here, NFE2L2 is linked to cancer.